1/9
12:46 pm
vrax
Virax Biolabs Group (NASDAQ:VRAX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $1.00 price target on the stock, down previously from $3.00.
Medium
Report
Virax Biolabs Group (NASDAQ:VRAX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $1.00 price target on the stock, down previously from $3.00.